Skip to content

More Than Just p-Values: MCID for the VAS, MSQ and FEMD in Patients With Primary Dysmenorrhea

More Than Just p-Values: Minimal Clinically Important Difference for the Visual Analog Scale, Menstrual Symptom Questionnaire and Functional and Emotional Measure of Dysmenorrhea in Patients With Primary Dysmenorrhea

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06835036
Enrollment
100
Registered
2025-02-19
Start date
2025-02-15
Completion date
2025-07-31
Last updated
2025-09-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Menstrual Discomfort, Pain, Primary Dysmenorrhea

Keywords

Dysmenorrhea, Menstruation, Visual Analog Scale, Minimal Clinically Important Difference, ROC Curve

Brief summary

The aim of this study is to determine the Minimal Clinically Important Difference (MCID) for the Visual Analog Scale (VAS), Menstrual Symptom Questionnaire (MSQ), and Functional and Emotional Measure of Dysmenorrhea (FEMD) in patients with primary dysmenorrhea (PwPD).

Detailed description

100 PwPD will receive functional exercises three times a week for three menstrual cycles. Patients will be assessed on the most painful days of the first (baseline), second, and third menstrual cycles. The receiver operating characteristics (ROC) method and Gamma coefficient analysis will be applied to determine the responsiveness.

Interventions

In this study, a functional exercise programme will be performed 3 days a week for 8 weeks in three cycles as previously recommended. This programme consisted of a 5-minute warm-up and a 45-minute exercise phase.

Sponsors

Artvin Coruh University
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

In this prospective study, one treatment group was formed to receive exercise treatment.

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 35 Years
Healthy volunteers
No

Inclusion criteria

* Diagnosis of PD according to the No. 345-Primary Dysmenorrhea Consensus Guideline, * Pain level of three or more according to VAS during activity (moderate to severe pain), * Patients aged 18-35 years (when PD becomes more prevalent), * Regular menstrual cycle with a duration of 28±7 days, * Nulliparity.

Exclusion criteria

* Historical background of chronic urogenital infections or drug use, * Pregnancy, * Secondary dysmenorrhoea caused by gynaecological conditions such as endometriosis, adenomyosis and uterine fibroids.

Design outcomes

Primary

MeasureTime frameDescription
Pain IntensityBaseline (On the most painful day of the menstrual cycle before the intervention)Pain intensity in the lower abdomen, lower back and both thighs will be assessed using a 10 cm Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (excruciating pain). Pain levels were categorised as 0-2 (safe), 3-5 (acceptable) and 6-10 (risky).

Secondary

MeasureTime frameDescription
Menstrual Symptom Questionnaire (MSQ)Baseline (On the most painful day of the menstrual cycle before the intervention)The Likert scale consists of 22 items, with responses rated on a 5-point range from 1 (never) to 5 (always). The scale includes three components: 'Negative Effects/Somatic Complaints' (items 1-13), 'Menstrual Pain Symptoms' (items 14-19), and 'Coping Methods' (items 20-22). The MSQ score is the mean value of all items in the scale. Increasing scores reflect more menstrual symptoms.
Functional and Emotional Measure of Dysmenorrhea (FEMD)Baseline (On the most painful day of the menstrual cycle before the intervention)The FEMD is a 14-item measurement tool that evaluates the functional and emotional aspects of dysmenorrhea using a 5-point Likert-type scale. The total scores on this scale range from 14 to 70, with higher scores indicating a more significant functional and emotional impact of dysmenorrhea on an individual.
Global Rating Change (GRC)After the 4-week intervention (On the most painful day of the first menstrual cycle after the start of the intervention)The GRC comprised seven responses, ranging from 1 to 7, indicating very much better, much better, slightly better, no change, slightly worse, much worse, and very much worse, respectively.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026